- The founder and chief medical officer of HealthRX.com gives patients three things to check before they buy from any telehealth company, his own included.
- I2CM Invites First 12 Companies to Join as Founding Members with Reduced First-Year Dues
- Phase 2b trial finds a consistent dose-response relationship on pain and other symptom measures and a prespecified subgroup analysis support further clinical development of the investigational oral combination
- A seasoned biotechnology executive who brings expertise that spans clinical practice, precision medicine and drug development using data and artificial intelligence
- Early career scientists from Students for Sensible Drug Policy (SSDP) — the largest youth-led grassroots network dedicated to ending the War on Drugs — join forces with a psychedelic drug developer in challenging the DEA’s proposed Schedule I placement of five tryptamines, warning of serious consequences for scientific research and promising medical treatments.
- A trauma nurse in Corpus Christi, Texas, founded BlackFox Media LLC to build the clinical references and exam-prep apps he wanted for his workflow, and all 14 work offline with no ads, accounts or tracking.
- VIORA and BioTeke have formalized an expanded partnership covering manufacturing, exclusive commercial rights across eight markets, and international distribution development, with both companies set to collaborate at MEDICA 2026.
- At an October 3, 2026, gathering of the Association of Yale Alumni in Medicine, physician Richard Low, MD, challenged a central assumption of healthcare AI: recording what physicians say is not the same as understanding their clinical reasoning.
- The company continues the European rollout of DBLG2 and prepares new features and expanded indications to simplify diabetes management and reach more people.
- Students for Sensible Drug Policy (SSDP) — the largest youth-led grassroots network focused on replacing the War on Drugs with policies rooted in science, compassion, and human rights — has fought against DEA efforts to restrict psychedelic research since 2022.
- [PRESSWIRE] Hoofddorp, The Netherlands / Bologna, Italy – 11 August, 2026 — SEVER Life Sciences B.V. (“SEVER”) today announced that it has signed a Share Purchase Agreement (“SPA”) for the sale of 100% of the shares in Nordic Group B.V. and its subsidiaries (“Nordic Group”) to Alfasigma S.p.A. (“Alfasigma”).
- Public opposition to the Drug Enforcement Administration’s (DEA) proposed ban on 7-hydroxymitragynine (7-OH), a naturally occurring metabolite of the kratom plant, has already surpassed the historic 2016 campaign that stopped the agency’s attempt to ban kratom. Students for Sensible Drug Policy (SSDP), the largest grassroots network dedicated to replacing the War on Drugs with policies rooted in science, compassion, and human rights, has created easy-to-use advocacy tools to help the public submit comments to the federal register opposing the criminalization of 7-OH and ask Congress to stop the emergency scheduling of SR-17018 ahead of the July 31 deadline.
- [PRESSWIRE] Clermont-Ferrand, France – July 21, 2026 — Sepul Bio, an innovative business unit of Laboratories Théa dedicated to advancing therapies for inherited retinal diseases, today announced the enrollment of the final participant in the Phase 2b LUNA clinical trial of Ultevursen in patients with Usher syndrome type 2A (USH2A)-associated retinitis pigmentosa (RP) or non-syndromic RP.
- Seasoned healthcare executive brings deep payer strategy, value-based care expertise, and proven scaling experience to rapidly growing mental health company
- [PRESSWIRE] GRENOBLE, France – 17 Juillet, 2026 — Diabeloop, entreprise pionnière dans l’intelligence artificielle thérapeutique pour la gestion du diabète, annonce aujourd’hui une avancée majeure et dès maintenant disponible pour les utilisateurs de son système de délivrance automatisée d’insuline DBLG1 : la possibilité de synchroniser désormais leurs données avec la plateforme de télésurveillance du diabète Glooko XT®. Cette intégration stratégique a pour objectif d’offrir aux professionnels de santé et aux patients un suivi fluide et optimal, spécifiquement pensé pour s’intégrer dans les parcours de soins.
- A new policy paper written by members of SSDP’s Science Policy Committee outlines recommendations for fixing the research barriers Congress intended to address but federal agencies have yet to implement.
- [PRESSWIRE] SEJONG, KOREA – July 14, 2026 — Azcuris Co., Ltd. announced that it has entered into a research collaboration agreement with AstraZeneca, a leading global biopharmaceutical company, to discover innovative therapies for respiratory and Th2-driven diseases. The collaboration was announced at the NOVA Global Connect 2026 event held in San Diego, California.
- [PRESSWIRE] GRENOBLE, France – July 10, 2026 – Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 Automated Insulin Delivery (AID) system, fully integrated with ViCentra’s Kaleido insulin patch pump and Dexcom G7 Continuous Glucose Monitoring (CGM), is now officially open for prescription in Germany (and the Netherlands later this summer).
- Students for Sensible Drug Policy (SSDP) urges the public to speak out before July 31 using its federal comment tool as the government moves to criminalize 7-hydroxymitragynine (7-OH) above a proposed threshold while advancing broader emergency Schedule I actions against promising opioid research compounds.
- Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is an interactive simulation and a preview of the virtual DBLG2 System.
- Funding Co-Led by a National Healthcare Insurance Company and AlleyCorp, with participation from Health Velocity Capital Investment accelerates technology-enabled, community-centered care model
- Veterans, Clinicians, Researchers, and Community Leaders Launch Carolinas for Care to Expand Safe, Evidence-Based Access to Psychedelic-Assisted Therapies Across North and South Carolina
- EBME Expo 2026 is less than a month away and promises to be the largest edition yet with more than 200 exhibitors taking part. Businesses are coming from across the UK, Europe, Asia and North America, including Turkiye, Germany, US, Italy, Pakistan, Holland and India, and a special feature will be a pavilion showcasing med-tech manufacturers and suppliers from China.
- Leadership transition reflects Company’s growth, operational maturity, and commitment to scaling recovery-oriented care for people living with serious mental illness…
- Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announced technical readiness, CE marking approval and the gradual European launch of its latest Automated Insulin Delivery (AID) system, DBLG2, integrated with Dexcom G7 Continuous Glucose Monitoring (CGM) system.
- [PRESSWIRE] DENMARK – 30 April, 2026 — °MEQU today announced that its °M Station has received clearance from the U.S. Food and Drug Administration, marking a major step forward in trauma care by enabling uninterrupted blood and IV fluid warming from the point of injury through hospital treatment.
- [PRESSWIRE] Monaco – 30 March, 2026 — EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company focused on regenerative innovation, today announced the scientific unveiling of BLŪPRIN™, its human exosome platform. This unveiling builds on EMA Aesthetics’s previously announced strategic relationship with MonoTx™, reinforcing a shared commitment to advancing next-generation regenerative innovation.
- [PRESSWIRE] 爱尔兰都柏林 —— 2026年3月11日 —— 总部位于都柏林的全球美学公司 EMA Aesthetics(www.emaaesthetics.com)宣布对 MonoTx Global Holdings, Inc.(MonoTx) 进行战略投资。此次投资将加强双方在下一代再生医学美容领域的合作,并为长期创新发展奠定更坚实的基础。
- 【PRESSWIRE】愛爾蘭都柏林 – 2026年3月11日 – 全球美學公司 EMA Aesthetics(www.emaaesthetics.com)欣然宣佈對 MonoTx Global Holdings, Inc.(「MonoTx」)進行策略性投資,進一步加強雙方於次世代再生美學領域的合作,並為長期創新奠定穩固基礎。
- [PRESSWIRE] Dublin, Ireland – 11th March, 2026 – EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company headquartered in Dublin, is pleased to announce a strategic investment in MonoTx Global Holdings, Inc. (“MonoTx”), strengthening the companies’ collaboration in next-generation regenerative aesthetics and expanding the foundation for long-term innovation.